Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer
- 1 November 2004
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (16) , 2403-2410
- https://doi.org/10.1016/j.ejca.2004.07.013
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Quality of Life in Goserelin-Treated Versus Cyclophosphamide + Methotrexate + Fluorouracil–Treated Premenopausal and Perimenopausal Patients With Node-Positive, Early Breast Cancer: The Zoladex Early Breast Cancer Research Association Trialists GroupJournal of Clinical Oncology, 2003
- Survival analyses from the ZEBRA studyEuropean Journal Of Cancer, 2003
- Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized StudyJournal of Clinical Oncology, 2003
- Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancerBritish Journal of Surgery, 2003
- Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5Journal of Clinical Oncology, 2002
- Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association StudyJournal of Clinical Oncology, 2002
- Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancerEuropean Journal Of Cancer, 2002
- Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments?Breast Cancer Research and Treatment, 2001
- Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized TrialJournal of Clinical Oncology, 2000
- Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trialThe Lancet, 1993